Tern Plc cuts Board pay and introduces shareholder distribution policy

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced a reduction in the fixed remuneration of Tern’s board and its executive management, together with a distribution commitment for when significant proceeds are received from exits of the Company’s investments.

As previously announced, the focus of the Board and Tern’s executive management team is on realisations and specifically seeking to maximise the value that can be realised from Tern’s portfolio companies and investments through successful exits from its investments at the appropriate time, ultimately seeking strong returns for shareholders.  At the same time the Company is maintaining strict control over operational costs and looking to make further savings where appropriate, in addition to the significant savings made in 2024 and the current financial year.

The Board have examined ways in which the operational costs of the Company can be further reduced, whilst aligning the interests of Tern’s Board and executive management with those of shareholders.  The Board, with the agreement of the executive management, have therefore resolved that:

·    Fixed remuneration reduction: From 1 November 2025 there will be a 50 per cent reduction in the salaries of the two Board directors, Jane McCracken and Iain Ross, and Tern’s executive managers Al Sisto and Bruce Leith.  This is expected to provide a saving of approximately £153,000 on an annualised basis.

·    Performance-aligned remuneration policy: The Board has adopted a remuneration policy whereby 12.5% of the net proceeds of any exit of the Company’s investments will be allocated to the executive team and Board, being those directly responsible for the Company’s capital allocation, strategy, and execution.

·    Shareholder distribution commitment: The Board has committed that shareholders will receive a distribution or capital return of at least 50% of the net proceeds received by the Company from the exit of any individual investment over £1 million (subject to the Company having sufficient distributable reserves and no legal or regulatory impediment to undertaking such an action).  

Commenting, Jane McCracken, Interim Non-Executive Chair of Tern, said: “We recognise that it is very important that management and shareholder interests are aligned, particularly during this capital-intensive phase of development of Tern’s investments.  The decision to reduce Board and executive management salaries by 50% will only have a modest financial impact on Tern, but coupling this with a fixed performance-based component of remuneration reflects our desire to signal a clear alignment of interests with shareholders.  This is not a discretionary bonus scheme, but a lean, outcome-driven policy designed to reflect the team’s scale of responsibility and the nature of our mandate.

“Our focus remains on realisations and we wish to give shareholders a clearer indication of what they can expect when we receive proceeds from exiting investments.  The Tern Board and management team are all working hard to deliver shareholder value and I look forward to providing further updates in due course.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

Search